{
    "Case ID": "001908",
    "Crime_Name": [
        "Intellectual Property Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity dispute"
    ],
    "Legal_Issue": [
        "Obviousness of the sildenafil patent for treating erectile dysfunction"
    ],
    "Governing_Law": [
        "Patent law"
    ],
    "Procedural_Stage": [
        "Pre-trial injunction / prohibition order application"
    ],
    "Evidence_Assessment": [
        "Advancements in understanding erectile dysfunction existed, but no direct evidence pointed to oral use of sildenafil as a PDE5 inhibitor prior to Pfizer's discovery"
    ],
    "Decision_Outcome": [
        "Patent is valid; Apotex's allegations of invalidity are unsubstantiated"
    ],
    "Burden_of_Proof": [
        "Pfizer met its burden of proving the patent's validity"
    ],
    "Credibility_Factor": [
        "Speculation existed but lacked definitive conclusions before Pfizer's invention"
    ],
    "Legal_Rule": [
        "A patent is invalid if the invention would have been obvious to a person skilled in the art at the time of invention"
    ],
    "Standard_of_Review": [
        "Whether the invention was obvious without experimentation"
    ],
    "Procedural_Issue": [
        "Application for a prohibition order to block generic approval"
    ],
    "Grounds_for_Claim": [
        "Obviousness"
    ],
    "Outcome_on_Merits": [
        "In favor of Pfizer"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "Not applicable – initial decision, not on review"
    ],
    "Review_Standard": [
        "Not applicable"
    ],
    "Procedural_Fairness_Assessment": [
        "Court conducted analysis on validity grounds including obviousness and anticipation"
    ],
    "Key_Evidence_Considered": [
        "Scientific knowledge on erectile dysfunction and PDE5 inhibitors prior to Pfizer's discovery"
    ],
    "Legal_Framework": [
        "Patent protection and regulatory exclusivity"
    ],
    "Applicant_Challenge": [
        "Apotex challenged the validity of Pfizer’s patent"
    ],
    "Court_Result": [
        "Granted Pfizer's application for prohibition order"
    ],
    "Legal_Rule_Source": [
        "Statutory patent law and legal precedents on non-obviousness"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Apotex claimed the patent was invalid due to obviousness"
    ],
    "Evidence_Type": [
        "Scientific and technical evidence"
    ],
    "Remedy_Requested": [
        "Prohibition order to prevent regulatory approval of generic version"
    ],
    "Outcome": [
        "Prohibition granted until patent expiration"
    ],
    "Decision_Authority": [
        "Court"
    ],
    "Remedy_Sought": [
        "Prevention of generic market entry prior to patent expiry"
    ],
    "Resolution_Mechanism": [
        "Judicial determination on patent validity"
    ],
    "Legal_Provision": [
        "Patent Act provisions on validity and infringement"
    ],
    "Authority": [
        "National court with jurisdiction over patent matters"
    ],
    "Claimant_Status": [
        "Pfizer as patent holder"
    ],
    "Legal_Provision_Cited": [
        "Patentability criteria, particularly non-obviousness"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Allegation of obviousness"
    ],
    "Applicable_Process": [
        "Regulatory linkage process requiring patent expiry before generic approval"
    ],
    "Outcome_of_Review": [
        "Not applicable"
    ],
    "Pending_Relief_or_Application": [
        "Prohibition order pending patent expiry"
    ],
    "Jurisdiction": [
        "National (implied: Canada or similar jurisdiction)"
    ],
    "Governing_Rule": [
        "Non-obviousness requirement for patent validity"
    ]
}